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2019;108:292–303 SHV SIZING AND LABELLINGThoracic Surgeons (STS) and the American Association
for Thoracic Surgery (AATS). The EACTS–STS–AATS
Valve Labelling Task Force, comprising cardiac
surgeons, cardiologists, engineers, regulators and repre-
sentatives from the International Organization for
Standardization (ISO) and major valve manufacturers,
held its first in-person meeting in February 2018 in Paris,
France. This article was derived from the meeting’s
discussions. The Task Force identified the following
areas for improvement and clarification: reporting of
physical dimensions and characteristics of SHVs deter-
mining and labelling of SHV size, in vivo and in vitro
testing and reporting of SHV hemodynamic perfor-
mance and thrombogenicity. Furthermore, a thorough
understanding of the regulatory background and therole of the applicable ISO standards, together with close
cooperation between all stakeholders (including regula-
tory and standard-setting bodies), is necessary to
improve the current situation. Cardiac surgeons should
be provided with appropriate information to allow for
optimal SHV choice. This first article from the EACTS–
STS–AATS Valve Labelling Task Force summarizes the
background of SHV sizing and labelling and identifies
the most important elements where further standardi-
zation is necessary.
(Ann Thorac Surg 2019;108:292–303)
 2019 by The Society of Thoracic Surgeons, The
American Association for Thoracic Surgery, and the
European Association for Cardio-Thoracic SurgeryIntroduction






Iminant of surgical success; using the most appropriate
surgical prosthetic heart valve (SHV) minimizes the risks
of surgery, maximizes hemodynamic performance and
optimizes long-term outcomes [1]. The final choice of an
SHV, including appropriate size, is typically made in the
operating theatre. To facilitate an evidence-based SHV
choice, sufficient appropriate information on SHV char-
acteristics is required. Background information from
medical literature is not available in the intraoperative
setting, so SHV package labels and instructions for use
(IFU) booklets are the primary sources of information for
the surgeon in the operating theatre.
In both the European Union (EU) and the USA, the
quality and quantity of information provided with an SHV
are regulated. The International Organization for Stan-
dardization (ISO) plays an important role in this process by
providing a framework for regulatory bodies [2]. Although
the ISO 5840 standard (Cardiovascular Implants—Cardiac
Valve Prostheses) provides general conditions for testing
SHVs for human implantation and defines operational and
labelling requirements, the current labelling situation is
not optimal. Simple definitions such as ’labelled valve size’
are often unclear, and inconsistencies and controversies
exist around the sizing and labelling of SHVs in relation to
hemodynamic performance [3].
To resolve these issues, the European Association for
Cardio-Thoracic Surgery (EACTS), The Society of
Thoracic Surgeons (STS) and the American Association
for Thoracic Surgery (AATS) set up the EACTS–STS–
AATS Valve Labelling Task Force, involving representa-
tives of the 3 surgical societies, cardiologists, engineers,
regulatory professionals and representatives from ISO
and major valve-manufacturing companies (complete list
of Task Force members is provided in the Appendix). The
discussions during the first in-person meeting of the Task
Force (held in February 2018, Paris, France) provided the
core content of this article.
This first article of the EACTS–STS–AATS Valve
Labelling Task Force is intended to provide an overview
of important characteristics of SHVs relating to sizing and
labelling, reviews current practices in these areas andidentifies where improvements are necessary. This article
will be followed by an expert consensus document con-
taining recommendations on SHV sizing and labelling.Regulatory Aspects and Use of Standards in
Prosthetic Heart Valve Labelling
In the EU and the USA, medical devices must demonstrate
conformity to the local legislations before they can be intro-
duced to themarket. Assessment of conformity is defined as
the evaluationofwhether a certaindevice is safe andeffective
according to the applicable regulations. This includes the
assessment of the device labelling information, including the
IFUandpackage labels.The ISOstandardsplayan important
role in defining these device-specific requirements.
International Organization for Standardization and the
Prosthetic Heart Valve Standards
Technical standards are formal documents, defining
uniform engineering criteria for technical systems. The
ISO is an independent, non- governmental organization
consisting of national standards bodies [4]. Manufacturers
globally use ISO standards during product development
and production. In addition, ISO standards are widely
utilized by regulatory bodies as a conformity assessment
tool for market approval. The ISO standards are period-
ically revised and updated in line with new innovations.
‘ISO 5840’ is a family of standards developed by a
group of professionals from engineering and medical
backgrounds, including representatives of the medical
device industry, regulators and clinicians. The current
2015 version (ISO 5840:2015, Cardiovascular Implants—
Cardiac Valve Prostheses) consists of 3 parts: ’part 1:
general requirements, part 2: surgically implanted heart
valve substitutes and part 3: heart valve substitutes
implanted by transcatheter techniques’. ‘ISO 5840:2015’
provides recommendations and requirements for pre-
clinical and clinical evaluations of SHVs [2], and it defines
valve-related objective performance criteria according to
linearized event rates of key safety end points (throm-
boembolism, valve thrombosis, hemorrhage, para-
valvular leakage and endocarditis) [2, 5, 6]. Furthermore,
ISO provides guidance on labelling by describing the
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information that should be available on the product labels
and in the IFU, including detailed information on inten-
ded use, indications/contraindications and warnings, and
physical and performance characteristics [2].
Standards and Prosthetic Heart Valve Approval in the
European Union
In the EU, the regulatory framework provided by the
European Commission sets the general requirements for
the whole range of medical devices [7, 8]. More specific
requirements are defined within ‘Common Specifica-
tions’ or in ‘Harmonized Standards’. The European
Committee for Standardization (CEN) cooperates with
the ISO, and existing ISO standards can be adopted as
‘Harmonized Standards’ endorsed by the European
Commission [9]. Furthermore, technical standards are
used as a tool to define the generally acknowledged ‘state
of the art’ in a certain field. To define ‘state of the art’,
other documents such as consensus documents by pro-
fessional societies are also taken into account during
conformity assessment [8].
In the EU, conformity assessment of medical devices is
performed by Notified Bodies. These are independent,
third-party organizations appointed by Member States.
Notified Bodies can grant the CE (European Conformity)
mark, which allows marketing a product within the
European Economic Area.
Standards and Prosthetic Heart Valve Approval in the
USA
In the USA, the medical device market is centrally regu-
lated by the Food and Drug Administration (FDA)
through review and approval of applications for new
devices [10]. During the process of approving new SHVs,
the use of ‘Consensus Standards’ by the FDA is voluntary
[11]. The ISO 5840 standards are recognized by the FDA
and could serve as a guidance for manufacturers when
submitting their applications for approval to the FDA [12].Design and Characteristics of Surgical Prosthetic
Heart Valves
Design and Materials
The design and component materials of an SHV should:
cause minimal harm to endothelial tissue and blood cells;
pose minimal chances for platelet and thrombus deposi-
tion; be resistant to structural wear and tear, mechanical
failure and degradation; be biochemically inert in a
physiological milieu; and be suitable for sterilization [13].
Mechanical valve leaflets and their supporting frames are
composed mostly of pyrolytic carbon. Bioprosthetic
valves, however, have more variation in their component
materials: both native valves from animals and valves
manufactured from animal pericardium are used
(Table 1). Preparation techniques used for biological
tissues aim to reduce immunogenicity [14], cross-link
collagen and prevent calcification to delay valve degen-
eration [15]. Polymeric heart valves might offer a rela-
tively inexpensive alternative to biological tissues, buttheir safety and effectiveness in the clinical setting are yet
to be proved [16, 17]. Differences in long-term outcomes
with various prostheses have been identified, which may
relate to specific design features [18, 19].
Materials used for the supporting frames of bio-
prosthetic valves vary in composition (Table 1), which is
potentially relevant for subsequent valve-in-valve trans-
catheter procedures, when bioprosthetic valve frame
fracture could enable insertion of a larger transcatheter
prosthesis [20]. Importantly, some bioprosthetic SHVs are
equipped with an expandable band, which is intended to
facilitate controlled expansion of the valve support
structure when subjected to radial force. Many SHVs are
equipped with radiopaque markers or have an intrinsi-
cally radiopaque support structure. This is useful when a
valve-in-valve procedure is planned, as it aids in posi-
tioning of the transcatheter valve and provides informa-
tion about the proximity of the SHV strut to the coronary
ostia. Currently, there is a considerable variety in radi-
opaque marking of bioprosthetic SHVs [21].
The ‘ISO 5840:2015’ standard contains recommenda-
tions on reporting the magnetic resonance imaging (MRI)
safety designation of the prosthesis in the accompanying
IFU. However, it does not require detailed reporting of
the materials used for SHV manufacturing.
Physical Dimensions
Physical dimensions of SHVs are closely related to their
performance, safety and ease of use, and can influence
the choice of prosthesis and the implantation technique.
Dimensions are defined in ‘ISO 5840:2015’ and should be
provided in the IFU [2]. However, reporting of these
measurements in terms of dimensional definitions is not
consistent, and the relationship between SHV physical
dimensions and the ‘labelled valve size’ is unclear,
creating confusion in the surgical community [3].
AXIAL DIMENSIONS. The fundamental axial dimensions of an
SHV are the overall ‘profile height’ and ‘outflow tract
profile height’, the latter being the maximum distance
that the heart valve substitute extends axially into the
outflow tract, measured from the valve structure’s inten-
ded annular attachment, according to ‘ISO 5840:2015’
(Figs 1 and 2) [2].
HORIZONTAL DIMENSIONS. The ISO-defined horizontal di-
mensions of an SHV are the ‘internal orifice diameter’ and
the ‘external sewing ring diameter’ (Figs 1 and 2). According
to ‘ISO5840:2015’, ‘internalorificediameter’ is ‘theminimum
diameter within a surgical heart valve substitute through
which blood flows’ [2], making it one of the most relevant
physical dimensions characterizing SHV performance.
A widely used parameter when selecting a trans-
catheter prosthesis during a valve-in-valve procedure is
the ‘true internal diameter’ (true ID) of the surgical bio-
prosthesis. This ‘true ID’ is measured by passing a Hegar
dilator through the bioprosthetic orifice and therefore
closely corresponds to the ISO-defined ‘internal orifice
diameter’ [22]. Of note, manufacturers often report
‘internal diameter (ID)’ or ‘stent internal diameter (stent
ID)’, which is the ID of the stent (label F in Figs 1 and 2).
Table 1. Component Materials in Stented Surgical Prosthetic Heart Valves
Stented Bioprostheses Mechanoprostheses
Leaflets Native porcine valve and bovine pericardium Pyrolytic carbon
Supporting frame/stent Titanium, Elgiloya and Delrinb Pyrolytic carbon and titanium
Sewing ring Silicone rubber and Dacronc Dacron and Teflond
a Cobalt–chromium–nickel–molybdenum alloy. b Acetal homopolymer. c Polyethylene terephthalate. d Polytetrafluoroethylene.
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occupied by the prosthetic leaflets in the orifice of a bio-
prosthetic valve (eg, the difference between labels C and
D in Figs 1 and 2).
LABELLED VALVE SIZE. Importantly, rather than being a
strictly valve-related physical parameter, labelled ‘valve
size’, according to ‘ISO 5840:2015’, is an indicator of the
‘tissue annulus diameter of the patient into whom the
surgical heart valve substitute is intended to be implan-
ted’ [2]. In other words, the labelled ‘valve size’ is not
based on any single valve-related physical dimension,
according to ISO definitions. This is a source of profound
confusion in the cardiac surgical community [23].
Another problem is the common erroneous perception
of a direct relationship between labelled valve size and
hemodynamic performance [24].Sewing Ring
The sewing ring enables an SHV to be secured to the
patient’s tissue annulus. Sewing rings must be biocom-
patible and capable of sustaining expected in vivo
loading.
INTRA- AND SUPRA-ANNULAR POSITIONING. The sewing ring
determines the position of the SHV in relation to the
patient’s tissue annulus. According to ‘ISO 5840:2015’, a
supra-annular sewing ring is a ‘sewing ring designed to
secure the valve “wholly above” the patient’s tissue
annulus’, while an intra-annular sewing ring is a ‘sewingring designed to secure the surgical heart valve “wholly
or mostly within” the patient’s tissue annulus’ [2].
Although there is some controversy surrounding exact
definitions of intra-annular and supra-annular positions
of the valve (Fig 3), this information is sometimes dis-
played on product labels or used in marketing materials.
Despite the design of an SHV, surgeons can implant most
valves in either intra- or supra-annular positions using
specific suturing techniques.
SEWING RING SHAPE AND SUTURE MARKERS. Sewing rings can
be designed as completely flat structures or can have a
curvilinear form that aims to provide alignment with the
patient’s non-planar anatomical annulus. Suture markers
on the sewing ring are intended to facilitate implantation
and correct orientation of the SHV. Currently, there is a
considerable variety in the number and position of suture
markers.
IMPLANTATION AIDS. Several implantation aids are provided
with an SHV, including handles, rotators or systems to
prevent inadvertent suture looping and/or facilitating
knot-tying. According to ‘ISO 5840:2015’, the use of these
implantation aids should be described in the IFU.Intraoperative Sizing
The goal of intraoperative sizing is to determine the
labelled size of the SHV that can be safely implanted into
the patient. This information, together with easy access to
information about the relevant properties (eg,Fig 1. Physical dimensions
of surgical prosthetic heart
valves, aortic position. (I)
Typical tissue valve. (II)
Typical bileaflet mechano-
prosthesis. (A) Overall
profile height; (B) outflow
tract profile height; (C) in-
ternal orifice diameter; (D)
internal diameter/internal










Fig 2. Physical dimensions of surgi-
cal prosthetic heart valves, mitral
position. (I) Typical tissue valve. (II)
Typical bileaflet mechanoprosthesis.
(A) Overall profile height; (B)
Outflow tract profile height; (C) In-
ternal orifice diameter; (D) Internal
diameter/internal stent diameter; (E)
external stent/housing diameter; (F)
external sewing ring diameter.
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hemodynamic performance, durability, thrombogenicity,
etc.) of the particular SHV that would fit, makes optimal
intraoperative valve choice possible.
SIZERS. Manufacturers provide a set of valve-related sizers
for each SHVmodel. Sizers are numbered according to the
labelled sizes of the corresponding SHVs. Typically, sizers
have 2 ends: a cylindrical end (barrel) to measure the
annulus and guide SHV selection based on the labelled
valve size, and a replica mimicking the configuration of the
prosthesis (Fig 4). Sizing with a replica after suture place-
ment is particularly useful because both the patient’s
anatomy and the surgeon’s suturing technique influence
the SHV’s final position and affect ultimate sizing [25, 26].
SIZERS AND THE LABELLED VALVE SIZE. Given that the
numbering of sizers follows the labelled valve size, the
sizer barrel should determine the diameter of the pa-
tient’s tissue annulus. Indeed, size measured using the
sizer barrel is not intended to provide direct information
regarding the physical dimensions of the corresponding
SHV [27]. However, numerous publications have
demonstrated significant differences between labelled
valve size and the actual dimensions of the valve-related
sizer barrel, causing confusion in the surgical community
[3, 28–30].
During labelling, the manufacturer determines which
valve is recommended for a measured tissue annulus,
which is reflected in the labelled valve size. However,Fig 3. Possible positions of a prosthetic heart valve in relation to the
aortic annulus (red line). (I) The valve is positioned in the annulus—
‘intra-annular’. (II) The valve ‘partially’ extends into the level of the
annulus—unclear situation. (III) The valve is ‘wholly’ above the
annulus—‘supra-annular’.clinical sizing can vary depending on the extent of
annular debridement or surgeon aggressiveness when
entering the sizer to the annulus. These variabilities make
it challenging for manufacturers to determine which
valve to recommend for implanting into a specific tissue
annulus diameter (ie, to determine the labelled valve
size). Although the actual tissue annulus diameter is
easily determined using a Hegar dilator or a similar cir-
cular sizing tool, these inconsistencies and challenges
mean that optimal sizing is currently best performed
using the set of sizers provided by the manufacturer with
the valve selected for implantation.Hemodynamic Performance of Surgical Prosthetic
Heart Valves
In Vitro Hydrodynamic Performance Testing
In vitro hydrodynamic testing is intended to assess the
ability of an SHV to enable forward flow and prevent
reverse flow and is required for device approval.
Although steady flow testers allow manufacturers to
measure forward flow and reverse flow (leakage) across
the SHV under controlled conditions, the testing envi-
ronment is very different from physiological conditions.Fig 4. Typical 2-ended valve sizer.
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‘ISO 5840:2015’ provides guidance for in vitro hydrody-
namic performance testing and defines flow hydrody-
namic acceptance criteria for pulsatile testing based on
valve size and implant position [2].
PULSATILE TESTING. Pulsatile testing enables SHV perfor-
mance tobeassessedunderphysiologicalflowandpressure
conditions that are similar to those inwhich it is intended to
function. Pulsatile testing enablesmeasurement offlowand
pressure drop (pressure gradient), calculation of the in vitro
effective orifice area (EOA) and total regurgitant volume
and fraction. In vitro EOA is derived from the mean pres-
sure difference and forward flowmeasured across the open
valve, while regurgitant fraction is the volume of fluid that
flows retrograde through the test valve as a percentage of
forward flow. These parameters are defined in ‘ISO
5840:2015’ [2]. In vitro EOA is calculated using the following
equation:






where EOA is measured in cm2, qV RMS is the root
mean square of forward flow (ml/s), Dp is the mean
pressure difference (mmHg) and q is the test fluid density
(g/cm3).
PULSE DUPLICATOR. Pulsatile testing is performed in a test
apparatus commonly known as a ‘pulse duplicator’. ‘ISO
5840:2015’ provides specifications for pulsatile testing to
reduce variability in testing and reportingmethods between
testing centres. These include specifications for the test
apparatus (pulse duplicator), measurement equipment ac-
curacy and test procedures [2]. However, pulse duplicators
are not perfect substitutes for human anatomy and the
physiological conditions in which the SHV is intended to be
used. Currently used pulse duplicators vary between test
centres and range from simple to sophisticated systemswith
different degrees of mimicking of the human anatomy.
These subtle differences in test environments have a pro-
found effect on the results of pulsatile testing. An inter-
laboratory round-robin study of SHV in vitro pulsatile
testing demonstrated considerable differences in results of
hydrodynamic performance measures in different test cen-
tres evaluating the same reference valves, using a common
ISO-derived protocol. In this study, measures of both for-
ward (EOA) and backward flow (regurgitant fraction) were
found to be subject to this effect [31]. Results of EOA and
regurgitant fraction measurements in the participating 6
centres are displayed on Figure 5, for a 25-mm bileaflet
mechanical (St. JudeMedical, St. Paul,MN) and for a 25-mm
tissue reference valve (Edwards Lifesciences, Irvine, CA).
This variation in in vitro hemodynamic performance mea-
surements mandates improved standardization of investi-
gational protocols to increase the reproducibility of test
results across different centres.
In Vivo Hemodynamic Performance Testing
The hemodynamic performance of most SHVs is inferior
to that of native healthy valves. Hence, the majority ofnormally functioning SHVs cause some degree of
obstruction to blood flow, depending on the model and
size of the SHV as well as the patient’s cardiac function.
Furthermore, several models of SHVs harbor some de-
gree of ‘physiological’ transprosthetic regurgitation,
which may be considered as part of washing the valve.
Doppler echocardiography is the primary imaging mo-
dality used to assess SHV hemodynamic function in vivo
[32, 33], although cardiac catheterization may also be
used.
Assessment of Forward Flow Hemodynamics
TRANSPROSTHETIC VELOCITY AND PRESSURE GRADIENTS. Tran-
sprosthetic gradients (DP) are measured using Doppler
echocardiography and the simplified Bernoulli formula:
DP ¼ 4 VPrV2;
where VPrV is the maximal transprosthetic velocity ob-
tained using continuous-wave Doppler echocardiography.
The peak velocity across the prosthesis is to some
extent related to valve size, with smaller SHVs having
higher velocities. However, in the case of normally
functioning aortic SHVs, VPrV is low, and in high cardiac
output or when the left ventricular outflow tract (LVOT) is
narrow, the velocity in the LVOT may not be negligible.
In these cases, the pressure gradient is more accurately
estimated by integrating the velocity proximal to the
prosthesis in the following Bernoulli equation:
DP ¼ 4 VPrV2  VLVOT2

Overestimation of the gradients may occur in the
presence of significant pressure recovery in any SHV, or
in cases of localized high velocities in mechanical SHVs,
as discussed later in this section.
VALVE GEOMETRIC AND EFFECTIVE ORIFICE AREAS. The geometric
orifice area (GOA) of the SHV is the area between the free
edges of the open leaflets of a bioprosthetic valve, or the
area created by the open spaces between the valve ring
and leaflet(s) for a mechanical SHV. The GOA represents
the area theoretically available for flow. Importantly,
GOA should not be mistaken for the internal orifice area,
which is the area calculated from the ID of the SHV stent/
housing. Typically, the GOA is smaller than the internal
orifice area, because internal orifice area does not account
for the space occupied by the leaflets in the SHV orifice
(Fig 6).
Similarly, the in vivo EOA is smaller than the GOA, as
it corresponds to the smallest area of the flow jet passing
through the prosthesis as it exits the valve (Fig 6). The
flow contraction coefficient (ie, the ratio EOA/GOA) var-
ies from 0.70 to 0.90. From a pathophysiological
perspective, transvalvular pressure gradients are more
closely related to EOA than to GOA.
The in vivo EOA is less flow-dependent than the trans-
prosthetic velocity or gradient, and is thus often a better
metric of intrinsic valve hemodynamic performance. For
both aortic and mitral SHVs, the EOA is calculated using
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the continuity equation method incorporating the stroke
volume measured in the LVOT using pulsed-wave
Doppler echocardiography:
in vivo EOA ¼ CSALVOT  VTILVOT
VTIPrV
;
where CSALVOT is the cross-sectional area of the LVOT,
calculated from the ID of the LVOT, measured just
proximal to the apical border of the SHV stent/sewing
ring; VTILVOT is the velocity–time integral (VTI) of blood
flow in the LVOT measured using pulsed-wave Doppler
echocardiography in the LVOT just proximal to the apical
border of the SHV stent/sewing ring; and VTIPrV is the
VTI through the SHV obtained using continuous-wave
Doppler echocardiography. It should be noted that each
of these parameters (CSALVOT, VTILVOT and VTIPrV) may
be subject to certain measurement errors [32, 34]. In
particular, the CSALVOT might be underestimated by
transthoracic echocardiography because the cross-section
of the LVOT is often elliptic and transthoracic echocar-
diography measures the smaller diameter of the ellipse.
Some studies therefore suggested to use 3D imaging
modalities (eg, 3D transoesophageal echocardiography
or multidetector computed tomography) to measureFig 5. In vitro round-robin
testing results. (I) EOA and
regurgitant fraction results
of a 25-mm bileaflet me-
chanical reference valve
(St. Jude Medical, St. Paul,
MN), determined by
in vitro pulsatile testing in
6 different centres [(A–F)
coded from light to dark
shades of green]. (II) EOA
and regurgitant fraction
results of a 25-mm tissue
reference valve (Edwards
Lifesciences, Irvine, CA),
determined by in vitro
pulsatile testing in 6
different centres [(A–F)
coded from light to dark
shades of green]. *Mini-
mum performance re-




from J Heart Valve Dis
2017;26:72–80, by Retta
et al. Reproduced by
permission.) (EOA ¼
effective orifice area; RF ¼
regurgitant fraction.)CSALVOT for EOA calculations [35]. However, this
approach did not demonstrate any incremental prognostic
value compared to standard EOA calculations based on
transthoracic echocardiography measurements [36, 37].
The normal reference values of EOA depend on the
SHV model and size. Therefore, to confirm that an SHV
has a normal function, the in vivo-obtained EOA should
be compared with the normal in vivo EOA value reported
for the same model and size of SHV [32]. Normal SHV
function is defined as an in vivo EOA that is within 1
SD of normal value for the corresponding model and
size of SHV [32, 38]. A difference of more than 2 SDs
between the normal reference value and the in vivo
EOA measured in the patient suggests prosthetic valve
stenosis [32].
DOPPLER VELOCITY INDEX (OR DIMENSIONLESS RATIO). For aortic
SHVs, the Doppler velocity index (DVI) is calculated as the
ratio of the VTI in the LVOT to the transprosthetic flowVTI:
DVI ¼ VTILVOT
VTIPrV
For mitral SHVs, the DVI is calculated as the ratio of the
transprosthetic flow VTI to the LVOT VTI:
Fig 6. IOA, GOA and EOA in bioprosthetic and mechanical valves.
(EOA ¼ effective orifice area; GOA ¼ geometric orifice area; IOA ¼
internal orifice area.)
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The DVI is 0.30 for a normally functioning aortic
SHV and <2.2 for a normally functioning mitral SHV.
The DVI has the advantage over the EOA of being less
subject to measurement variability and less dependent
on SHV size.
PRESSURE RECOVERY AND LOCALIZED HIGH GRADIENT. In patients
with an aortic SHV and small aorta relative to the valve
EOA, a substantial proportion of the pressure generated
by the left ventricle might initially be lost between the
LVOT and the vena contracta of the SHV flow, but may be
recovered downstream to the vena contracta (Fig 7). This
phenomenon is called pressure recovery and may occur
with both native and prosthetic valves.
Given that Doppler echocardiography measures the
highest VPrV and thus transprosthetic gradient at the level
of the vena contracta, and that cardiac catheterization
measures the aortic pressure and gradient downstream of
the vena contracta (and thus downstream of the pressure
recovery phenomenon), Doppler echocardiography may
yield higher values of gradients and smaller values of
EOA compared with catheterization (Fig 7). Failure to
take ’pressure recovery’ into account may lead to over-
estimation of the transprosthetic gradient and underes-
timation of the EOA using Doppler echocardiography,
especially in patients with an ascending aortic diameter<30 mm. It is possible to correct the EOA for the extent of
pressure recovery by calculating the energy loss coeffi-
cient (ELC). The ELC adjusts the Doppler EOA for the
size of the ascending aorta in order to account for the
extent of pressure recovery:
ELC ¼ EOAAA
AA EOA;
where AA is the cross-sectional area of the aorta
measured about 1 cm downstream of the sinotubular
junction [39]. The ELC, in fact, provides an estimate of the
EOA measured by catheterization.
In bileaflet mechanical valves, a localized high velocity
may be recorded using continuous-wave Doppler echo-
cardiography through the central orifice of the valve,
which is often smaller than the 2 lateral orifices. This may
yield an overestimation of the transvalvular gradient (by
an average of 5–15% compared with cardiac catheteriza-
tion) and underestimation of the EOA [40].
Assessment of Physiological Prosthetic Heart Valve
Regurgitation
All mechanical SHVs have a regurgitant volume (2–10 ml)
that includes a closing volume (necessary for closing the
occluders) and/or a washing/leakage volume (through
the components), which contribute to the prevention of
blood stasis and thrombus formation. Normal leakage
backflow jets are narrow at their origin, often symmetri-
cal, and have a homogeneous color without significant
aliasing (Fig 8). Of note, trace (<1 ml) central leakage may
also occur in normally functioning bioprosthetic valves. It
is important to separate physiological from pathological
prosthesis regurgitation.
The approach for detecting and grading SHV regurgi-
tation is similar to that for native valves and involves color
Doppler imaging in multiple views and planes as well as
measurement of several Doppler echocardiographical
parameters [32, 41]. There are limited data on the appli-
cation and validation of semi-quantitative and quantita-
tive parameters such as width of the regurgitant jet or of
the vena contracta, the effective regurgitant orifice area,
and the regurgitant volume and fraction in the context of
prosthetic valves [42]. Given that all parameters of SHV
regurgitation have important limitations and may be
subject to measurement errors, a comprehensive, multi-
parametric integrative approach is recommended [32, 41].
Cardiac MRI using phase-contrast sequences may be
helpful to quantitate SHV regurgitation [43].
Prosthesis–Patient Mismatch
Prosthesis–patient mismatch (PPM) after surgical aortic
valve replacement (SAVR) occurs when a patient receives
an SHV that has insufficient EOA relative to cardiac
output requirements.
After indexing EOA to the body surface area (BSA),
PPM after SAVR is considered to be ‘moderate’ if the
indexed EOA is 0.66– 0.85 cm2/m2, and ‘severe’ if indexed
EOA is 0.65 cm2/m2 [32]. In obese patients [body mass
index (BMI) 30 kg/m2], it is recommended to use lower
cut-off values of indexed EOA to define ‘moderate’ and
Fig 7. Pressure recovery. (I) Large aorta diameter, minimal
pressure recovery. Pressure gradients between the LVOT and
VC, and between the LVOT and AA are similar. (II) Small
aorta diameter, significant pressure recovery. Pressure gra-
dients between the LVOT and VC, and between the LVOT
and AA are different. (AA ¼ ascending aorta; LVOT ¼ left
ventricular outflow tract; PAA ¼ ascending aortic pressure;
PLVOT ¼ left ventricular outflow tract pressure; PR ¼ pres-
sure recovery; DPAA ¼ pressure gradient between the LVOT
and the ascending aorta; DPVC ¼ pressure gradient between
the LVOT and the vena contracta; VC ¼ vena contracta.)
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‘severe’ PPM (0.56–0.70 and 0.55 cm2/m2, respectively)
[32, 44]. In a meta-analysis of 34 studies on PPM after
SAVR, the rates of moderate and severe PPM were 34.2%
and 9.8%, respectively [1]. Predictors for PPM are female
sex, larger BSA, larger BMI, diabetes, hypertension and
renal failure [45]. Mechanical valves generally have a
slightly larger EOA than bioprosthetic valves with the
same labelled size, and they are associated with lower
PPM rates [46].
The presence of PPM results in higher postoperative
residual transvalvular gradients, which have been asso-
ciated with less left ventricular mass regression, worse
functional class and quality of life, higher risk of hospi-
talization due to heart failure and higher short- and long-
term mortality rates after SAVR [1, 47]. Furthermore,
studies have suggested that structural valve degenerationFig 8. Normal regurgitant
jet in bioprosthetic and
mechanical valves. Normal
‘physiological regurgitant’
jets (orange arrows) in (A)
a stented bioprosthetic
aortic valve and in (B) a
bileaflet mechanical mitral
valve.is accelerated if PPM is present [48]. In summary, PPM
after SAVR impacts prognosis at various follow-up stages,
and prevention of PPM should be a priority, especially in
young, active patients and those with left ventricular
systolic dysfunction.
A tool for predicting PPM after SAVR is available:
multiplying the patient’s BSA by 0.85 calculates the
minimum EOA value required to prevent PPM, thus
allowing surgeons to select an appropriate SHV to obtain
the desired EOA [49]. In cases where the aortic annulus is
too small to fit an acceptable valve, aortic annulus or root
enlargement may be considered to facilitate implantation
of a larger prosthesis. Reliable data on EOA are critical to
the success of this strategy.
Valve manufacturers have provided valve-specific
charts that can be used intraoperatively to predict PPM.
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Ideally, comparing these charts would allow the surgeon
to select the optimal valve for the patient to avoid PPM.
However, accurate prediction of severe PPM using these
charts has been reported to be as low as 59% [50].
Moreover, these charts have been severely criticized for
lack of uniformity: different cut-offs were used to define
PPM; in some instances, in vitro data were used to
determine EOA and in vivo echocardiographical studies
were occasionally selected to include those with the
largest EOA values. Furthermore, even normal reference
values of SHV hemodynamic performance reported in
the literature are derived mostly from single-centre
studies without core laboratory evaluation of SHV func-
tion [32]. These issues render effective prevention of PPM
challenging.
Thrombogenicity of Prosthetic Heart Valves
The risk of bleeding and thromboembolic events after
SHV implantation depends on the type and anatomical
position of the prosthesis, anticoagulation strategy and
patient-related risk factors, such as hematological disor-
ders, arrhythmias and cardiac chamber dilatation or
function. ‘ISO 5840:2015’ defines objective performance
criteria for bleeding and thromboembolic events for the
clinical evaluation of SHVs [2, 5, 6].
North American and European clinical practice guide-
lines provide recommendations on postprocedural anti-
coagulation after mechanical and bioprosthetic valve
replacement [51, 52]. In contrast to bioprosthetic SHVs,
mechanical valves require lifelong anticoagulation with
vitamin-K antagonists. Treatment with vitamin-K antag-
onists carries certain risks and demands rigorous patient
compliance. To date, no viable alternative to vitamin-K
antagonists in this setting has been identified [53, 54],
but numerous studies have been performed to investigate
the safety of a lower international normalized ratio (INR)
target in patients with mechanical valves in the aortic
position [46, 55]. In the EU, 2 mechanical SHVs have
received regulatory approval for reduced anticoagulation,
if used in the aortic position in patients with low risk for
thromboembolic events [54, 56]; this information is often
displayed on the device packaging and used in marketing
materials. However, there are no comparisons among
currently used valves, so it cannot be concluded whether
a lower INR is safe in only those 2 valves or also in others
[46]. Indeed, clinical practice guidelines categorize me-
chanical SHVs on the basis of their thrombogenicity, with
most contemporary mechanical valves falling into the
‘low thrombogenicity’ category [51, 52], and several
studies with the use of mechanical valves not specifically
approved for lower INR ranges have also shown
improved safety and similar efficacy with lower INR
ranges [46, 55].
In bioprosthetic valves, the issue of subclinical leaflet
thrombosis has been raised recently [57, 58] and clearly
deserves further study. It remains unclear whether bio-
prosthetic valve thrombosis occurs more frequently with
some valves compared with others or why the rate is
lower in SHVs than in transcatheter valves [58].
Comparative studies are needed to differentiatethrombotic risk among various valves. These should be
carefully evaluated before statements are made on anti-
coagulation for bioprostheses, which would have possible
ramifications for labelling.Discussion
Sizing and labelling of SHVs are complex issues that span
the domains of clinical practice, engineering and product
manufacturing, and have important regulatory aspects.
Currently, many unanswered questions surround intra-
operative sizing and labelling of SHVs, making optimal
intraoperative SHV selection challenging. These include:
1. non-uniform or incomplete reporting of SHV mate-
rials and physical dimensions in the IFU;
2. unclear definition of labelled valve size and in-
consistencies between sizer dimensions and labelled
valve size;
3. non-uniform marking of SHV support structures;
4. lack of robust information on in vivo hemodynamic
performance in the IFU, and no information available
regarding hemodynamic performance on package
labels;
5. lack of uniform tools backed by solid evidence to
prevent PPM; and
6. lack of good-quality, robust clinical data on SHV
thrombogenicity.
This situation has persisted for decades and has
received many calls for action, but no uniform solution
has been achieved to date.
Determining the right amount of information for
intraoperative decision-making requires finding a deli-
cate balance. Although currently available parameters on
the package labels provide incomplete information
regarding the most important characteristics of the SHV,
the inclusion of redundant or irrelevant information
would similarly create confusion in the surgical
community.
Complex issues are best prioritized and solved through
concentrated efforts from all critical stakeholders [59].
The EACTS–STS–AATS Valve Labelling article Project
has been initiated with this intention. The medical com-
munity requires clarity and should work together with
valve manufacturers, regulatory bodies and the ISO
group to achieve an optimal solution. This article has
summarized the most important characteristics of SHVs
and the background of SHV labelling and is intended to
pave the way for an EACTS–STS–AATS Expert
Consensus Document that will include recommendations
on SHV sizing and labelling.Conclusion
This joint EACTS–STS–AATS Labelling Task Force has
identified several issues related to SHV sizing and label-
ling. These issues should be addressed to ensure that
surgeons are provided with sufficient, appropriate and
standardized information required for optimal SHV choice.
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